State Street Corp Grows Position in Avantor, Inc. (NYSE:AVTR)

State Street Corp lifted its holdings in Avantor, Inc. (NYSE:AVTR - Free Report) by 58.0% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 22,368,244 shares of the company's stock after acquiring an additional 8,206,695 shares during the period. State Street Corp owned 3.29% of Avantor worth $578,666,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Blue Trust Inc. boosted its holdings in shares of Avantor by 1,830.3% in the 2nd quarter. Blue Trust Inc. now owns 1,467 shares of the company's stock worth $31,000 after purchasing an additional 1,391 shares during the period. UMB Bank n.a. purchased a new position in shares of Avantor during the third quarter valued at approximately $49,000. Nisa Investment Advisors LLC grew its stake in shares of Avantor by 69.6% during the third quarter. Nisa Investment Advisors LLC now owns 2,035 shares of the company's stock valued at $53,000 after buying an additional 835 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of Avantor by 89.9% during the 3rd quarter. GAMMA Investing LLC now owns 2,715 shares of the company's stock worth $70,000 after acquiring an additional 1,285 shares during the last quarter. Finally, ORG Partners LLC grew its position in Avantor by 5,773.0% in the 2nd quarter. ORG Partners LLC now owns 5,873 shares of the company's stock valued at $122,000 after acquiring an additional 5,773 shares during the last quarter. Hedge funds and other institutional investors own 95.08% of the company's stock.

Avantor Price Performance

Shares of Avantor stock traded up $0.70 on Monday, hitting $22.09. The company's stock had a trading volume of 6,550,235 shares, compared to its average volume of 6,485,205. The company has a market capitalization of $15.03 billion, a price-to-earnings ratio of 46.50, a price-to-earnings-growth ratio of 2.59 and a beta of 1.29. The firm has a fifty day moving average price of $22.78 and a 200-day moving average price of $23.58. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.06 and a current ratio of 1.54. Avantor, Inc. has a 1 year low of $19.59 and a 1 year high of $28.00.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on AVTR shares. Barclays dropped their price target on Avantor from $28.00 to $25.00 and set an "overweight" rating on the stock in a research report on Friday, October 25th. Wells Fargo & Company reduced their price objective on shares of Avantor from $30.00 to $28.00 and set an "overweight" rating for the company in a research note on Monday, October 28th. Royal Bank of Canada reiterated an "outperform" rating and issued a $34.00 price target on shares of Avantor in a report on Thursday, September 26th. UBS Group decreased their price objective on Avantor from $30.00 to $29.00 and set a "buy" rating for the company in a research note on Tuesday, October 8th. Finally, Robert W. Baird decreased their price target on shares of Avantor from $27.00 to $26.00 and set an "outperform" rating for the company in a research report on Monday, October 28th. Three research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $27.69.

Avantor Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.